Parent Project Muscular Dystrophy Hosts 2025 Annual Conference in Las Vegas, Nevada

Annual event brings together 1,200 plus families, physicians, researchers, caregivers, industry partners, and those living with Duchenne and Becker in person and virtually to connect, share information, and learn the latest progress in the fight to end Duchenne.

LAS VEGAS, June 18, 2025 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will host its 2025 Annual Conference in Las Vegas, Nevada, June 19–21. Each year, the Duchenne and Becker community gathers to learn about the latest progress in care, therapeutic developments, and connect with leading experts. Now in its 31st year, PPMD's Annual Conference comes to Las Vegas to engage the Duchenne and Becker community.

PPMD expects 1,200 plus families, researchers, clinicians, and industry partners from all over the world for three days of informative and interactive sessions featuring the latest news in research, clinical trials, approved and emerging therapies, care initiatives, quality of life issues, and more.

Founded in 1994 by a group of parents and grandparents, and led by Founding President and CEO Pat Furlong, PPMD is the largest, most comprehensive nonprofit organization in the United States focused on ending Duchenne. Since its first meeting 31 years ago, PPMD has convened families with researchers, clinicians, industry partners, advocacy organizations, and most importantly, people with Duchenne and Becker and their families at the largest Duchenne-specific conference held in the U.S.

Furlong looks forward to bringing the community together at Conference: "This past year has brought both hard-won progress and painful setbacks. As we gather, we reflect and recommit, surrounded by the extraordinary strength and determination that define this community. I'm deeply grateful for the opportunity to come together at this year's Annual Conference—to connect, to learn, and to keep moving forward, together. This gathering will be filled with meaningful conversations and the shared energy we need to continue driving progress in the fight to end Duchenne."

PPMD is grateful to all of our industry sponsors, whose support helps make the Annual Conference possible, especially our Elite sponsors Sarepta Therapeutics and Capricor Therapeutics, our Platinum sponsors ITF Therapeutics and NS Pharma, Inc., and our Gold sponsors Avidity Biosciences, BioMarin Pharmaceutical, Catalyst Pharmaceuticals, Dyne Therapeutics, Edgewise Therapeutics, Entrada Therapeutics, Keros Therapeutics, PTC Therapeutics, Satellos, Solid Biosciences, and Wave Life Sciences. For sponsorship opportunities, please click here.

PPMD's 2025 Annual Conference agenda will feature stories from keynote speaker Dr. Albert Freedman, and interactive discussion panels addressing comprehensive, multi-dimensional approaches to care for Duchenne and Becker. Unique topics to this year's conference include:

• The evolving steroid landscape and considerations for endocrine and bone health.
• Becker-specific breakout sessions, including discussions on neuromuscular care, cardiology, exercise, and physical therapy, as well as industry updates about emerging therapies for Becker.
• Exploring the gene therapy landscape; understanding immune responses, how we got here and where we're going.
• Cardiac and neuromuscular care for carriers, as well as key insights on carrier provider screening and muscle biopsy.
• Unique experiences and perspectives on life, living, and hope, as well as daily life care such as exercise, behavior, mental health, and decision-making; fostering relationships; managing family dynamics; and more.

A variety of breakout sessions and social gatherings will also be offered during PPMD's 2025 Annual Conference, encouraging attendees to create their own, unique experiences, in-person or virtually, by participating in:

• Special programming for Newly Diagnosed Families
• A dedicated track for Teens and Adults with Duchenne/Becker
• Expanded Sibs Track sessions, offering a safe place for siblings to be together, talk, and open up about topics that they face
• Breakout sessions according to age, covering multiple aspects of care
• One-on-one private appointments with Physical and Occupational Therapists, PPMD's genetics and Duchenne Registry team, and behavior, speech, and language experts to help provide guidance on every family's unique needs
• Small group Wellness Workshops focused on offering space for reflection, connection, and real conversations about life with Duchenne and Becker
• A robust Resource Fair enabling resource providers and the community to connect about practical services, research, and more
• A meet and greet for diverse families in Duchenne to share their unique experiences and foster connection
• Social activities for carriers, dads, grandparents, siblings, and, of course, tweens, teens, and adults with Duchenne and Becker
• Fun and interactive sessions for kids

Ahead of the Conference, all registered attendees were given access to PPMD's online Conference Hub & App to stream sessions and personalize their agenda and Conference experience. This year's Hub & App offers an enhanced experience for both in-person and virtual attendees, allowing for engagement with exhibitors and increased interaction during live sessions. AI-powered live translation will also be available for main sessions in dozens of languages, sponsored by Entrada Therapeutics and ITF Therapeutics.

It is not too late to attend this year's meeting, in-person or virtually. To register for PPMD's 2025 Annual Conference, click here. To learn more about PPMD, please visit our website.

About Parent Project Muscular Dystrophy

Duchenne is a genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) fights every single battle necessary to end Duchenne.

We demand optimal care standards and ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won eight FDA approvals.

Everything we do—and everything we have done since our founding in 1994—helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. Join our fight against Duchenne at EndDuchenne.org. Follow PPMD on Facebook, Twitter, Instagram, and YouTube.

SOURCE Parent Project Muscular Dystrophy (PPMD)